OncoGenex prices $50 million public offering
Friday, March 16, 2012
OncoGenex Pharmaceuticals, a biopharmaceutical company dedicated to new cancer therapies, has priced an underwritten public offering of 4,165,000 shares of its common stock at a purchase price of $12.00 per share.
Net proceeds from the offering will approximately amount to $46.8 million, after estimated underwriting discounts and commissions and estimated expenses. OncoGenex granted the underwriters a 30-day option to purchase up to an additional 624,750 shares of common stock to cover overallotments, if any.
The offering is expected to close on or around March 21, 2012, subject to customary closing conditions.